Image-guided radiation therapy vendor ViewRay is highlighting a prospective clinical trial that confirmed the safety of using its MRIdian MRI-guided radiation therapy to treat prostate cancer.
For the phase II prospective clinical trial, the researchers from Amsterdam University Medical Center in the Netherlands evaluated the efficacy of MRI-guided radiation therapy for 101 patients with intermediate- or high-risk prostate cancer. They found that there were no adverse events associated with high-grade toxicity in the genitourinary (GU) and gastrointestinal (GI) systems (International Journal of Radiation Oncology, Biology, Physics, August 13, 2019).
The group did detect low-grade toxicity in the GU system of 23.8% of the patients and the GI system of 5% of the patients. However, this low level of toxicity was comparable to levels typically observed in treatments for patients with low-risk prostate cancer, suggesting that MRI-guided radiation therapy minimized damage to surrounding tissue compared with standard treatment, the researchers noted.
"We see a lower incidence of GI and GU toxicity with MR-guidance as compared to similar stereotactic body radiation therapy prostate cancer studies," principal investigator Dr. Anna Bruynzeel, PhD, said in a statement.